We studied interleukin ( IL ) -12 gene therapy using a gene gun as a new autologous vaccination strategy for cancer. In the first experiment, BALB / c mice were inoculated with syngeneic murine renal cancer cells ( Renca ) intradermally in the abdomen. This was followed by an injection of IL -12 expression plasmid using the gene gun. About 40% of the mice exhibited rejection of the tumor after the treatment and these mice also acquired immunological resistance against a secondary challenge with Renca cells. Based on these results, we examined whether antitumor activity can be potentiated when mice undergo combination treatment with intradermal inoculation of irradiated Renca cells and transfection with IL -12 gene. Inoculation of irradiated Renca cells alone was partially effective in inducing antitumor immunity, whereas the combined treatment remarkably intensified this effect. Moreover, this combined treatment inhibited tumor establishment and enhanced survival of the mice with tumor infiltration by CD4 + and CD8 + T cells, even when the treatment was started after tumor -implantation at a distant site. This antitumor effect was antigen specific and we confirmed the induction of antitumor cytotoxic T cells by this treatment. These results show that local cutaneous transfer of IL -12 expression plasmid using gene gun technology enhances systemic and specific antitumor immunity primed by irradiated tumor cells.
U nder physiological conditions, cytokines are produced locally as the need arises. Therefore, systemic administration of recombinant cytokines for cancer treatment may cause severe side effects that limit dose and effectiveness of the treatment. Although interleukin ( IL) -12, which induces maturation of cytotoxic T lymphocytes ( CTL ), 1 development of T helper 1 (Th1 ) cells, 2 activation of natural killer (NK) cells 3 and inhibits tumor angiogenesis, 4 has profound antitumor effects in the murine tumor model, 5 systemic administration of recombinant IL -12 protein has been reported to cause severe toxicity in human clinical trials. 6, 7 IL-12 gene therapy using gene gun technology has been shown to exhibit a remarkable antitumor effect without toxicity in murine models. 8, 9 Rakhmilevich et al reported that transfer of the IL -12 gene into the skin overlying murine tumors using a gene gun effectively eradicates established primary intradermal tumors and their spontaneous metastasis. 10 These antitumor effects are mediated primarily by CD8 + T cells, which lead to the development of tumorspecific immunological memory. This IL -12 gene therapy protocol is nontoxic on account of the slow release of transgenic IL -12 protein and, in a comparative study, superior to therapies using other cytokine genes such as interferon ( IFN )-, tumor necrosis factor (TNF ) -, granulocyte -macrophage colony -stimulating factor (GM -CSF ), IL -2, IL -4 or IL-6. 8, 9 However, from the clinical point of view, this approach is practical only for skin cancers such as melanoma or cutaneous T-cell lymphoma, 8 but not for other types of cancer.
In an attempt to develop IL-12 gene therapy using a gene gun as a new autologous vaccination strategy for cancer, we examined whether antitumor immunity can be induced by a combination treatment using inoculation of irradiated tumor cells and transfection of the IL -12 gene. This approach is safer and more convenient than other methods because viral vectors are not used and transfection of the gene ex vivo is not required.
Materials and methods

Animals and tumors
Male BALB /c mice between 8 and 10 weeks of age were purchased from Shizuoka Laboratory Animal Center ( Hamamatsu, Japan ).
Renca, a spontaneously arising murine renal carcinoma originating in BALB /c mice, was maintained in vitro in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 IU /mL penicillin, 100 g /mL streptomycin, 20 mM N 0 -2 -hydroxyethylpiperazine -N 0 -2-ethanesulfonic acid, 50 mM NaHCO 3 and 2 mM L -glutamine. Renca cells (10 5 or 5Â10 5 ) in 0.1 mL of phosphate -buffered saline ( PBS ) were injected intradermally into the mice. We confirmed the expression of MHC class I molecules on Renca cells by flow cytometric analysis (data not shown ). Tumors were measured twice a week using a caliper and tumor volume was calculated as /6Â[(aÂb) 1 / 2 ] 3 , where a and b are two perpendicular major diameters.
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Plasmid IL -12 expression plasmid was constructed by inserting mouse IL -12 p35 and p40 cDNA into the unique EcoRI site between the CAG promoter and a 3 0 -flanking sequence of the rabbit -globin gene of the pCAGGS as previously described. 12 To express the IL -12 p35 /p40 heterodimer under a CAG promoter, an internal ribosomal entry site was cloned between IL -12 p35 and p40. For control treatment, mice were transfected with pCAGGS expression plasmid.
In vivo gene transfer
We used the Helios Gene Gun (Bio -Rad, Hercules, CA ) as previously described. 12 Briefly, plasmid DNA was precipitated onto 1.6-m gold particles and coated onto the inner surface of tubing by a tube loader. The final tubing segments resulted in delivery of 0.125 mg gold particles and 2 g plasmid DNA per transfection. Plasmid DNA was delivered to shaved abdominal skin of mice at 300 psi of helium pressure.
Determination of IL -12 mRNA in the draining lymph nodes
After 24 or 48 hours of gene transfection to the abdominal skin of mice via two injections using the Gene Gun, total RNA was purified from the draining lymph nodes using ISOGEN ( Wako, Osaka, Japan ) according to the manufacturer's protocol. Single -strand cDNA was synthesized from 2 g of total RNA by using a First -Strand cDNA Synthesis Kit (Pharmacia Biotech, Tokyo, Japan ). For IL-12, the sense and antisense primers were 5 0 -TCTGACTGACCGCGT-TACTCCCAC -3 0 and 5 0 -ATGTGCTGGTTTGGTCCCG-TGTGAT-3 0 , respectively. For -actin, the sense and antisense primers were 5 0 -ATGTGCACAGAAAGCAT-GATC -3 0 and 5 0 -AGATGA -TCTGAGTGTGAGGG -3 0 , respectively. The reaction mixture for PCR contained cDNA derived from 100 ng of total RNA, 20 pmol of sense and antisense primers, 1 U of Taq DNA polymerase (TaKaRa Taq, TaKaRa Shuzo, Kyoto, Japan ), and 200 pmol each of deoxynucleotide triphosphates, in a final volume of 50 L. Amplification was performed in sequential cycles, including 1 -minute denaturation at 948C, 1 -minute primer annealing at 568C, and 1.5 -minute extension at 728C using the Gene Amp PCR system 2400 (Perkin -Elmer, Norwalk, CT ). Amplification was carried out for 40 cycles. The PCR products were electrophoresed in a 2% agarose gel, and the gel was stained by ethidium bromide.
The IL -12 forward primer was designed to hybridize with the sequence immediately downstream of the transcription start site of the CAG promoter and, thus, the IL -12 primer pair could amplify IL -12 cDNA derived from pCAGGS -IL -12, but not from endogenous IL-12. The expected size of the PCR product from pCAGGS -IL-12 mRNA was 410 bp and that from -actin was 576 bp.
Protocol of direct tumor therapy
Mice were injected intradermally with 5Â10 5 Renca cells into the shaved abdominal area, and IL -12 expression plasmid or control plasmid were transferred into the skin overlying and surrounding the target tumor on days 1, 3, 5, and 7 after tumor implantation. Each treatment consisted of three transfections. One transfection was directly over the tumor site, and two additional treatments were evenly spaced around the circumference of the tumor. This treatment protocol was a modification of that described by Rakhmilevich et al. 10 
Prophylactic protocol
We inoculated the mice intradermally in the abdominal area with 5Â10 5 irradiated (X -ray, 5000 rad ) Renca cells in 0.1 mL PBS on day 21 and then on days 21 (after 4 hours of the inoculation with irradiated Renca cells ), 19, 17, and 15 before a challenge we transferred IL -12 expression plasmid or control plasmid to the abdominal skin overlying and surrounding the tumor cells. Each treatment consisted of three transfections. As a control, we injected 0.1 mL PBS. We used four treatment groups: (a ) PBS and control vector ( PBS /pCAGGS ); (b ) PBS and IL -12 ( PBS /IL -12); (c ) irradiated Renca and control vector ( Renca /pCAGGS ); and ( d) irradiated Renca and IL -12 (Renca/ IL-12). The mice were challenged with 5Â10 5 Renca cells intradermally in the breast area ( Fig 1A ) .
In vivo depletion of immune cell subsets
To evaluate the relative contributions of T cells in antitumor immunity, antibodies corresponding to each T-cell subset were administered to mice that had undergone combination treatment with intradermal inoculation of irradiated Renca cells and transfection with IL-12 gene along the prophylactic protocol ( Fig 1A ) . Anti -CD4 mAb ( clone GK1.5 ) and /or anti -CD8 mAb ( clone 53 -6Á72 ) were injected intraperitoneally at 0.5 mg per injection per mouse on days 1, 3 before, and days 2, 5, and 8 after the tumor challenge. Depletion of each T-cell subset was confirmed by flow cytometric analysis, and 95% of the cells of the appropriate subsets were regularly found to be depleted. Normal rat IgG ( Sigma, St. Louis, MO ) was used as mock control.
Cytotoxicity assay
On day 0 of the experiment along the prophylactic protocol ( Fig 1A ) , the mice were sacrificed and their spleen cells (5Â10 6 ) were cocultured with 10 5 mytomicin C -treated Renca cells in 24-well culture plates in complete RPMI 1640 media. After culturing for 5 days in vitro, graded numbers of viable effector cells and [
3 H ]thymidine -labeled Renca cells (10 4 ) were placed into the round -bottomed wells of 96-well plates. After 4.5 hours of incubation, the cells and their media were harvested and counted using a beta counter, and specific killing calculated. 13 
Therapeutic protocol
We inoculated the mice intradermally with 10 5 or 5Â10 5 Renca cells in the breast area as a tumor challenge on day 0, and a total of 2Â10 6 irradiated Renca cells or 0.2 mL PBS ( control ) at bilateral sites in the abdominal area via two injections (10 6 Renca cells / injection) on day 1. On days 1, 3, 5, and 7 after a tumor challenge, we transferred IL -12 expression plasmid or control plasmid (pCAGGS ) to the abdominal skin. Each treatment consisted of three transfections. Two transfections were directly over the inoculated sites of irradiated Renca cells, and one additional treatment was performed at the center of the abdominal area. We used four treatment groups: (a ) PBS / Cancer Gene Therapy Fig 1B ) .
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Immunohistochemical evaluation
To assess tumor infiltration by CD4 + and CD8 + T lymphocytes in the experiment along the therapeutic protocol ( Fig 1B ) , tumors grown from inoculation of 5Â10 5 Renca cells were excised on Day 8. Acetone -fixed cryostat sections were incubated for 90 minutes with monoclonal antibodies against CD4 (L3T4 ) or CD8 ( Lyt -2; both from Southern Biotechnology Associates, Birmingham, AL ). After washing, the sections were overlain with biotinylated goat anti -rat immunoglobulin (Vector Laboratories, Burlingame, CA ) for 30 minutes. Unbound immunoglobulin was removed by washing, and the slides were incubated for 30 minutes with VECTASTAIN R Elite ABC Reagent (Vector Laboratories ). Sections were incubated in peroxidase substrate solution for staining. To quantify CD4 + and CD8 + T-cell infiltration into tumor tissues, individual cells were counted under a microscope Â400 field (Â40 objective and Â10 ocular lens; 0.120 mm 2 per field ). Because the tumor tissue exhibited variable degrees of necrosis and variable distribution of T-cell infiltrates, only fields of nonnecrotic tumor containing the highest T-cell numbers were included in the analysis. 14 Ten samples were examined on the one treatment group.
Statistical analysis
Statistical analysis of survival rate and tumor free rate used the Kaplan -Meier method. The log rank test was used to assess the influence of treatments.
Results
Detection of IL -12 mRNA in the draining lymph nodes
The expression of IL-12 protein was observed in the genetransfected skin tissue 12 without elevation of serum IL-12 and IFN -levels ( data not shown). Gold particles coated with plasmid DNA could not be delivered to the intradermal tumor cells by gene gun (data not shown). Based on data from previous papers, which showed that genes delivered to the skin by gene gun technology are expressed in dendritic cells ( DCs ) localized in the draining lymph nodes, 15 -17 we attempted to detect IL -12 mRNA in these lymph nodes. The expression of IL -12 mRNA derived from pCAGGS -IL -12 was confirmed in axillary lymph nodes 48 hours after skin transfer of the IL -12 gene using gene gun by RT-PCR ( Fig 2 ) .
Antitumor effect of direct IL -12 gene therapy using gene gun technology on Renca tumor growth To evaluate the antitumor effect of gene gun -mediated IL -12 gene therapy, we delivered the IL-12 or control gene into the skin overlying and surrounding the intradermal Renca tumor on days 1, 3, 5 and 7 post tumor cell implantation (Protocol of direct tumor therapy in Materials and Methods ).
IL -12 gene therapy showed a remarkable antitumor effect ( Fig 3B ) compared with the control (Fig 3A ) , and about 40% of the mice in the IL -12 gene therapy group exhibited tumor cell rejection (Fig 3B and C ) . IL-12 gene therapy also significantly improved survival of the mice inoculated with Renca cells (Fig 3C ) . The mice that had rejected Renca cells following IL -12 gene therapy readily acquired resistance Figure 4 Induction of antitumor immunity using the prophylactic protocol ( Fig 1A ) . The mice were challenged with 5Â10 5 Renca cells intradermally on day 0. *Significant difference between Renca / IL -12 and other groups ( P < .05 ). Similar results were obtained in three separate experiments.
Figure 5 Effects of in vivo depletion of CD4
+ and / or CD8 + subsets of T cells on the antitumor response induced by inoculation of irradiated Renca cells followed by IL -12 gene therapy along the prophylactic protocol ( Fig 1A ) . Similar results were obtained in three separate experiments.
PBS /pCAGGS
Renca /pCAGGS Renca /IL-12 ( Fig 1A ) was used. Similar results were obtained in two separate experiments.
Cancer Gene Therapy
Cancer vaccine therapy using the gene gun M -a Nishitani et al against a second challenge with Renca cells at 2 months after primary inoculation (data not shown).
Gene gun -mediated transfection with IL -12 gene enhances antitumor immunity
Based on the result that mice that had rejected Renca cells following IL -12 gene therapy acquired resistance against a second challenge with Renca cells, we evaluated whether antitumor immunity is induced by a combination treatment using intradermal inoculation of irradiated Renca cells and transfection with IL -12 expression plasmid ( Fig 1A ) . Tumor rejection was observed in 80% of the mice in the Renca / IL -12 group, but in only 20% of the mice in the Renca / pCAGGS group and in no mice in the PBS /pCAGGS or the PBS /IL -12 groups ( Fig 4 ) . A single inoculation of irradiated Renca cells only partially induced antitumor immunity, whereas the combination treatment with IL-12 gene transfection showed a significant effect. In addition, this antitumor effect was antigen -specific, because tumor rejection was not observed when the mice were challenged with 5Â10 5 MethA sarcoma cells, which also originate in BALB /c mice (data not shown ).
CD8 + T cells are the main effector T -cell subset for antitumor immunity induced by combination treatment
To identify the relative contribution of T-cell subsets, mice that had undergone combination treatment with intradermal inoculation of irradiated Renca cells and transfection with IL -12 gene along the prophylactic protocol ( Fig 1A ) were depleted of specific T-cell subsets by the administration of corresponding antibodies before the induction of antitumor immunity. In vivo depletion of both CD4 + and CD8 + T cells completely abrogated the antitumor effect. Depletion of CD8 + T cells alone had only a partial effect, whereas depletion of CD4 + T cells alone did not affect the antitumor 
Cancer Gene Therapy
Cancer vaccine therapy using the gene gun M -a Nishitani et al immunity (Fig 5) . These results suggest that this antitumor effect is mainly CD8 + T cell -dependent but is also supported by CD4 + T cells.
CTL activity induced by combination treatment
To further evaluate antitumor immunity induced by the combination treatment along the prophylactic protocol ( Fig 1A ) , splenocytes isolated from each group of mice were assayed for CTL activity. Although splenocytes from Renca/ pCAGGS generated a higher level of CTL activity than those from PBS /pCAGGS or PBS /IL -12, the activity of splenocytes from Renca/ IL-12 was about 2-fold higher than that of Renca /pCAGGS ( Fig 6) . These results are consistent with results shown in Figure 4 .
Combination treatment induces a therapeutic antitumor effect at a distant site
We evaluated the therapeutic activity of combination treatment with intradermal inoculation of irradiated Renca cells and transfection with the IL -12 gene at a site distant from the tumor ( Fig 1B ) . By challenge with 10 5 Renca cells, all of the mice in the PBS /pCAGGS group developed tumors, but about 70% of the mice in the Renca /IL -12 group rejected Renca cells. Tumor establishments in the Renca /IL -12 group were significantly inhibited compared to those in other groups ( P <.05 ) (Fig 7A ) , and survival of the mice in the Renca/IL -12 group was also significantly enhanced compared to those in the three other groups (P < .01 ) (Fig 7B ) . In addition, the mice in the PBS /IL -12 group showed significantly increased survival compared to the mice in the PBS /pCAGGS group and the Renca/ pCAGGS group ( P <.05 ) (Fig 7B ) .
After challenge with 5Â10 5 Renca cells, 30% of the mice in the Renca/IL -12 group and none of the mice in three other groups rejected Renca cells. Survival of the mice in the Renca/IL -12 group was significantly enhanced compared to those in the three other groups (P < .05) (Fig 7C ) .
Immunohistochemical features
On day 8 of the experiment along the therapeutic protocol ( Fig 1B ) , marked infiltration of CD4 + and CD8 + lymphocytes was observed in the tumors treated with Renca /IL -12, whereas little infiltration of CD4 + and CD8 + lymphocytes was observed in the tumors treated with PBS /pCAGGS or Renca/ pCAGGS. In the tumors treated with PBS / IL-12, mild infiltration of CD4 + and CD8 + lymphocytes was observed (Fig 8, Table 1 ).
Discussion
Transfer of the IL -12 gene into the skin overlying murine tumors using a gene gun has been shown to exhibit a remarkable antitumor effect without toxicity in murine models. 8, 9 This antitumor effect is -mediated primarily by CD8 + T cells, which leads to the development of tumorspecific immunological memory. 10 However, from the clinical point of view, this approach is practical only for skin cancers such as melanoma or cutaneous T-cell lymphoma, 8 but not for other types of cancer. In the present study, we applied IL -12 gene therapy using gene gun technology to autologous cancer vaccine therapy. We used irradiated nonreplicating live cells of BALB/ c-originated Renca as antigen in this study. Priming of BALB /c mice with these cells induced antitumor immunity to some extent. Furthermore, IL -12 gene therapy significantly intensified this effect ( Figs 4 and 6 ). These results show that local cutaneous transfer of IL -12 expression plasmid using gene gun technology enhances systemic antitumor immunity primed by specific tumor antigen. Cytotoxic CD8 + T cells supported by CD4 + T cells were confirmed to be the main effector cells in this system (Fig 5 ) .
The enhancement of antitumor immunity by IL -12 gene therapy appears to be induced through strengthening of cross -priming activity. Cross -priming is a phenomenon in which exogenous antigens from donor cells, such as tumor cells or virus -infected cells, are captured and processed by bone marrow -derived host antigen-presenting cells ( APCs ), then presented directly on the major histocompatibility complex ( MHC ) class I molecules. Through this mechanism, class I-restricted CD8 + CTL is activated by corresponding exogenous ( foreign ) antigens. 18, 19 This type of antigen -presentation pathway is called an alternative MHC class I pathway. DCs play the important role as APCs in cross -priming, 20 and cross -priming of CTL requires CD4 + T cells. 21 IL-12 is considered an essential cytokine in these processes. 22 In our system, we propose that antigens from irradiated tumor cells were presented by APC such as cutaneous Langerhans' cells (a type of DCs ), and that the transfer of the IL -12 gene induced a Th1 dominant immune response 12 and enhanced cross -priming, thereby activating CD8 + CTL. Furthermore, the IL -12 gene appears to be transferred directly to Langerhans' cells, because genes delivered to the skin by gene gun technology have been shown to be expressed in Langerhans' cells localized in the draining lymph nodes. 15 -17 We confirmed the expression of IL -12 mRNA derived from IL -12 expression plasmid in the draining lymph nodes ( Fig 2) . Nishioka et al 23 demonstrated that intratumoral injection of DCs expressing the IL -12 gene induces systemic and therapeutic antitumor immunity, resulting in regression of established tumors.
In the experiment along the therapeutic protocol (Fig 1B ) , gene gun -mediated IL -12 gene transfer alone could induce 
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Cancer vaccine therapy using the gene gun M -a Nishitani et al a more prominent antitumor response and a higher tumor infiltration by CD4 + and CD8 + T cells than vaccination with irradiated tumor cells alone ( Figs 7B and 8 ) , Table 1 . However, in the experiment along the prophylactic protocol ( Fig 1A ) , vaccination with irradiated tumor cells alone could induce far superior cytotoxic activity than IL -12 gene transfer alone ( Fig 6) and antitumor immunity to some extent (Fig 4) . There are two possible solutions to this discrepancy. First, it is considered that the influence of IL -12 gene therapy had vanished at the point of tumor challenge and killing assay in the experiment along the prophylactic protocol ( Fig 1A ) . Our previous study 12 showed that the expression of IL -12 by gene gun -mediated transfection is significant at the site of gene transfection 1 day after the treatment, but rapidly decreases to background level after 3 days. Second, it is suggested that although vaccination with irradiated tumor cells alone could not induce tumor infiltration by primed CD4 + and CD8 + T cells in the therapeutic situation, IL -12 gene therapy accelerated tumor infiltration by these cells. Tannenbaum et al 14 reported that the regression of the mouse Renca tumor by recombinant IL-12 treatment was associated with the elevated expression of the IFN --inducible chemokines IP-10 and Mig within the tumor tissue, which have been shown to function as chemoattractants for activated T cells. In combination treatment with intradermal inoculation of irradiated Renca cells and transfection with the IL -12 gene, the antitumor effect of IL -12 gene therapy using gene gun technology is considered to be exerted by not only enhancement of cross -priming activity but also acceleration of tumor infiltration by primed CD4 + and CD8 + T cells. Angiostatic response to IL -12 gene therapy may also be relevant to the antitumor effect of this treatment 4 and should be examined in the future.
We used Renca cells that were spontaneously arising murine renal carcinoma in the present study. Renal cell carcinoma (RCC ) is a common urological cancer, but metastatic cases have poor prognosis because of their resistance to radiation or chemotherapy. Systemic administration of recombinant cytokines such as IFN -, IFN -, or IL -2 has been the primary treatment for those cases, although the outcome is not always satisfactory. Alternative new immunotherapies for RCC are expected because of its relatively high immunogenicity, 24 -26 and good results have been reported for several clinical trials. 27, 28 In particular, an immunological approach using induction of CTL, has been considered promising, because the expression of human leukocyte antigen class I molecules is preserved at a high rate in RCC. 29, 30 Vaccination with cytokine gene -transfected tumor cells has been reported to be effective for inducing CTL against unknown tumor antigens in animal models 31, 32 and already applied to human cancer as an autologous vaccine. 33 -35 However, this approach has some problems in a clinical situation, including safety concerns for viral vectors and the complexity of the technique. Our approach with combination treatment by intradermal inoculation of irradiated tumor cells and transfection with IL -12 gene using gene gun technology is safer and more convenient than vaccination with cytokine gene -transfected tumor cells because viral vectors are not used and transfection of the gene ex vivo is not required in our system. Our approach is considered to be a new autologous vaccination strategy for cancer.
